Status:
UNKNOWN
A Multicenter Registry of Adalimumab in Chinese Adult Patients With Active Ankylosing Spondylitis
Lead Sponsor:
Peking Union Medical College Hospital
Conditions:
Spondylitis, Ankylosing
Eligibility:
All Genders
18+ years
Brief Summary
A multicenter registry to explore the clinical outcome of Chinese adult patients with active Ankylosing Spondylitis \*AS\* treated with adalimumab,prescribed according to the local label,in the real w...
Detailed Description
This registry will be conducted in a non-interventional setting for AS patients using adalimumab in China.The primary objective is to evaluate the effectiveness and safety of adalimumab in Chinese AS ...
Eligibility Criteria
Inclusion
- Adult patients with established diagnosis of ankylosing spondylitis.
- Patients eligible to use adalimumab according to the local label without any contraindication.(According to the local label, patients should be screened for active infection,TB,HBV,malignancy and CHF before the prescription of adalimumab,patients with latent TB should start a full course of anti-TB therapy before the use of adalimumab.)
Exclusion
- Patients with contraindication or are not appropriate to use adalimumab according to the local label will be excluded
Key Trial Info
Start Date :
April 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2015
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT01901627
Start Date
April 1 2013
End Date
June 1 2015
Last Update
July 17 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking Union Medical College Hospital
Beijing, China, 100730